about
Treatment of dyslipidemia in allogeneic hematopoietic stem cell transplant patientsHigh Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD CohortDrug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease.Withholding statins in patients with underlying liver disease: wise or unwise?The Effects of Melatonin on Elevated Liver Enzymes during Statin Treatment.Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury networkHepatotoxicity Associated with a Short Course of Rosuvastatin.MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation.Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages.Predicting and preventing acute drug-induced liver injury: what's new in 2010?Drug-induced autoimmune-like hepatitis.Diagnosis and treatment of autoimmune hepatitis.Clinical perspective: statins and the liver--harmful or helpful?Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.Statins and liver injury.Drug-induced liver injury: an overview over the most critical compounds.Hepatotoxicity of statins and other lipid-lowering agents.Rationale for the use of statins in liver disease.Nonalcoholic fatty liver disease: from lipid profile to treatment.Clinical and histological features of idiosyncratic liver injury: Dilemma in diagnosis of autoimmune hepatitis.Acute hepatic injury with atorvastatin: an unusual occurrence.Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.Chlorzoxazone, an SK-type potassium channel activator used in humans, reduces excessive alcohol intake in rats.Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.Recurrence and Severe Worsening of Hepatotoxicity After Reintroduction of Atorvastatin in Combination With Ezetimibe.Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen.Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis.GGPPS deficiency aggravates CCl4-induced liver injury by inducing hepatocyte apoptosis.Atorvastatin treatment softens human red blood cells: an optical tweezers study.Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for “Safer Drug” Formulation that Prevents Drug-induced Liver Injury.High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins
P2860
Q26996051-5AD15009-7500-432C-822E-BAA7821FB843Q28550768-533999DD-DBF2-4303-B10C-9E5ABA291346Q33563872-6421A6F9-631B-4339-AF6F-3A773B8496C2Q33763729-44874E34-4B1E-45B7-A20D-A986915CF537Q33786661-F3BCE58F-5C9E-4C23-BB2E-DDADD6568243Q33946592-F6661054-5C78-4F6F-94E2-EF7D92CEE12EQ36523234-3EE8F6EF-D35B-4177-A064-E3698B8B4629Q37071691-E1C65B8C-61C5-4805-BD04-E8D9BCECFD5AQ37724173-00599B3C-AF07-400B-A220-1574B13F42D9Q37771029-3E72042B-7B72-493D-AB5B-DF2C023D2D85Q37843783-1662CEDA-1781-4899-BD15-B107A86579A6Q37969669-94D820FD-D097-438A-9C78-C123423B30DCQ38009719-5BCDCAD4-E736-4C97-B500-38EEFE57820BQ38166445-9FB094F3-3174-4E23-BB58-22A5DCC62425Q38204369-89001A73-DE40-454D-87CC-41EF45E5BC97Q38331202-CF42F4B9-3827-4AFC-B430-06530FE6B487Q39012464-9E208B0A-B059-4B80-B3BF-BCA9ECDADC2FQ39171942-3EDEB3C3-D38C-484E-BEFD-F391AF20AC25Q40729988-329A445F-4255-479B-9403-C0D943F4F870Q40995506-28BA0A14-6716-4113-A287-F543F8F8B3EEQ41229799-396C691D-8218-4D78-8013-808C888A8138Q41528115-4ED2E9B2-B361-425A-BE33-42D01E00A9F5Q41848559-A8FFA56A-EC55-4268-9AAC-B38085807AD3Q41977512-09903ADB-19FD-43B8-966B-3D95BD581288Q42254484-8C6A5558-3ED3-4C08-AECA-934A2BDCB05CQ42365140-48A2141B-6AA4-4261-9D5F-6C3237682260Q46577508-1D1664FC-93CF-4B59-990E-AE06377C36E9Q52564491-F768235E-AB21-4261-9703-5A34906CA4FBQ53566281-564E7154-3FE9-40DE-B266-138A0B73E1BEQ54944532-56FB2DA5-F02D-4633-BA4E-6C11E2DB333BQ55313239-48E4101B-CF19-44D9-A69F-655E1ED473B6Q58680687-E1487959-1848-4381-8114-4A6DDD1A9F71
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug-induced liver injury associated with statins.
@en
Drug-induced liver injury associated with statins.
@nl
type
label
Drug-induced liver injury associated with statins.
@en
Drug-induced liver injury associated with statins.
@nl
prefLabel
Drug-induced liver injury associated with statins.
@en
Drug-induced liver injury associated with statins.
@nl
P2093
P356
P1476
Drug-induced liver injury associated with statins.
@en
P2093
Herbert L Bonkovsky
Mark W Russo
Martin Scobey
P304
P356
10.1055/S-0029-1240010
P577
2009-10-13T00:00:00Z